Abstract
Molecular imaging (MI) is revolutionizing biology and medicine. Yet, for the full potential of MI to be realized, new, improved chemistries and targets are required. One such target is the peripheral benzodiazepine receptor (PBR). PBR is an 18kD trans-mitochondrial membrane protein involved in steroidogenesis and other mitochondrial function1,2. Furthermore, PBR has an expression profile making it a viable molecular target for the study of mitochondrial function and its relationship to cancer cell proliferation3,4. Capitalizing on these observations and the availability structural identity of PBR ligand, our group has synthesized a variety of PBR targeted imaging agents (visible fluorescence, NIR, MRI) based on a conjugable form of PK11195 (a PBR ligand)5. These ligands have been used for both in- vitro and in-vivo PBR targeted molecular imaging. It will be shown that these agents can be visualized in a variety of PBR over-expressing cell lines and that the quantification of uptake provides physiologically relevant information. Targeted in-vivo imaging results will also be presented showing that our PBR ligands may be useful for early disease detection and surgical resection guidance.
© 2004 Optical Society of America
PDF ArticleMore Like This
Darryl J. Bornhop, Padmaja Sattu, Steven Robertson, Garry E. Kiefer, David Morgan, and Barbara C. Pence
MD4 Biomedical Optical Spectroscopy and Diagnostics (BIOMED) 2000
Laura Marcu, P. Thomas Vernier, H. Charles Manning, Sarah Salemi, Aimin Li, Cheryl M. Craft, Martin A. Gundersen, and Darryl J. Bornhop
5141_64 European Conference on Biomedical Optics (ECBO) 2003
Konstantin Sokolov, Jesse Aaron, Sonia Kumar, Vivian Mack, Lezlee Coghlan, Ann Gillenwater, Karen Adler Storthz, Michele Follen, and Rebecca Richards Kortum
FThK2 Frontiers in Optics (FiO) 2004